Clinical Trials
14 trialsNCT04248829 2026-05-28
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
Phase 3 Completed
NCT02296125 2026-04-21
FLAURA
AstraZeneca
Phase 3 Completed
NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT03849768 2023-01-20
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT01544179 2020-09-25
IMPRESS
AstraZeneca
Phase 3 Completed
NCT01404260 2017-01-27
ISCAN
Guangdong Association of Clinical Trials
Phase 3 Completed
NCT00357734 2016-08-30
Iressa Follow-up Trial
AstraZeneca
Phase 3 Completed
NCT01017874 2015-07-08
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
Eli Lilly and Company
Phase 3 Completed
NCT00088907 2015-05-06
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00049543 2015-01-01
Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01040780 2014-02-14
ICOGEN
Betta Pharmaceuticals Co., Ltd.
Phase 3 Completed
NCT00322452 2013-11-07
IPASS
AstraZeneca
Phase 3 Completed